ImmunoVaccine Technologies Inc. (IVT) announced today that it has met with Health Canada’s regulatory affairs division, the Biologics and Genetic Therapies Directorate, to discuss requirements for a Phase I clinical trial application. For Phase I human clinical trials, IVT plans to combine novel antigens with its vaccine-enhancement technology, the VacciMax® platform.

“We are seeing impressive pre-clinical results with the VacciMax® platform,” said Dr. Randal Chase, president and CEO of IVT. ”The comments from the Biologics and Genetic Therapies Directorate are much appreciated because they give us direction as we proceed with our clinical development in Canada,” said Dr. Chase.

IVT will be in Phase I clinical trial in the U.S. as a result of its acquisition of Immunotope, a Pennsylvania-based company. The Phase I trial is evaluating the safety of candidate antigens for a therapeutic vaccine in ovarian and breast cancer patients.

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

The company, using its proprietary VacciMax® platform, is able to stimulate an earlier, more powerful, long lasting immune response that could provide a new way to treat cancer and infectious diseases.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

For more information, please contact:
Brian Lowe, Vice President
ImmunoVaccine Technologies Inc.

Jennifer Ayotte
Impact Communications Group

Halifax, Nova Scotia, January 23, 2008